This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bartalena, L, E Martino, A Pacchiarotti, L Grasso, F Aghini Lombardi, L Buratti, G Bambini, M Breccia, and A Pinchera. 1987. Factors affecting suppression of endogenous thyrotropin secretion by thyroxine treatment: retrospective analysis in athyreotic and goitrous patients. J Clin Endocrinol Metab 64:849–855.
Belfiore, A, D Russo, R Vigneri, and S Filetti. 2001. Graves’ disease, thyroid nodules and thyroid cancer. Clin Endocrinol (Oxford) 55:711–718.
Biondi, B, S Fazio, C Carella, G Amato, A Cittadini, G Lupoli, L Saccà , A Bellastella, and G Lombardi. 1993. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 77:334–338.
Burmeister, LA, MO Goumaz, CN Mariash, and JH Oppenheimer. 1992. Levothyroxine dose requirements for thyrotropin suppression in the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 75:344–350.
Cooper, DS, B Specker, M Ho, M Sperling, PW Ladenson, D Ross, KB Ain, ST Bigos, JD Brierley, BR Haugen, I Klein, J Robbins, SI Sherman, T Taylor, and HR Maxon III. 1999. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 8:737–744.
Dulgeroff, AJ, and JM Hershman. 1994. Medical therapy for differentiated thyroid carcinoma. Endocrinol Rev 15:500–515.
Faber, J, and AM Galloe. 1994. Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis. Acta Endocriol (Copenhagen) 130:350–356.
Fazio, S, B Biondi, C Carella, D Sabatini, A Cittadini, N Panza, G Lombardi, and L Saccà . 1995. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: beneficial effect of β-blockade. J Clin Endocrinol Metab 80:2222–2226.
Hung, W, and NJ Sarlis. 2002. Current controversies in the management of pediatric patients with well-differentiated non-medullary thyroid cancer: a review. Thyroid 12:683–702.
Ludgate, M, V Gire, M Crisp, R Ajjan, A Weetman, M Ivan, and D Wynford-Thomas. 1999. Contrasting effects of activating mutations of GαS and the thyrotropin receptor on proliferation and differentiation of thyroid follicular cells. Oncogene 18:4798–4807.
Marcocci, C, F Golia, E Vignali, and A Pinchera. 1997. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine. J Bone Miner Res 12:72–77.
Mazzaferri, EL, and SM Jhiang. 1994. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418–428.
McGriff, NJ, G Csako, L Gourgiotis, CG Lori, F Pucino, and NJ Sarlis. 2002. Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. Ann Med 34:554–564.
Parle, JV, P Maisonneuve, MC Sheppard, P Boyle, and JA Franklyn. 2001. Prediction of all-cause and cardiovascular mortality in elderly people from one low serum thyrotropin result: a 10-year cohort study. Lancet 358:861–865.
Pujol, P, JP Daures, N Nsakala, L Baldet, J Bringer, and C Jaffiol. 1996. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 81:4318–4323.
Sawin, CT, A Geller, PA Wolf, AJ Belanger, E Baker, P Bacharach, PWF Wilson, EJ Benjamin, and RB D’Agostino. 1994. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 331:1249–1252.
Shapiro, LE, R Sievert, L Ong, EL Ocampo, RA Chance, M Lee, M Nanna, K Ferrick, and MI Surks. 1997. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab 82:2592–2595.
Shen, DH, RT Kloos, EL Mazzaferri, and SM Jhiang. 2001. Sodium iodide symporter in health and disease. Thyroid 11:415–425.
Uzzan, B, J Campos, M Cucherat, P Nony, JP Boissel, and GY Perret. 1996. Effects on bone mass of long term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 81:4278–4289.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Mazzaferri, E.L. (2005). Effects of Suppressing Thyrotropin on Tumor Growth and Recurrence. In: Amdur, R.J., Mazzaferri, E.L. (eds) Essentials of Thyroid Cancer Management. Springer, Boston, MA. https://doi.org/10.1007/0-387-25714-4_34
Download citation
DOI: https://doi.org/10.1007/0-387-25714-4_34
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-25713-6
Online ISBN: 978-0-387-25714-3
eBook Packages: MedicineMedicine (R0)